Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
NPPA releases Revised MRP for 543
brands of Anti-Cancer Medicines; List to
be updated on continual basis; New
Prices Effective from November 9, 2026
Posted On: 28 OCT 2026 6:44PM by PIB Delhi
The National Pharmaceutical Pricing Authority (NPPA), under the Department of
Pharmaceuticals, Ministry of Chemicals and Fertilizers, has...
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals NPPA releases Revised MRP for 543 brands of Anti-Cancer Medicines; List to be updated on continual basis; New Prices Effective from November 9, 2026
Posted On: 28 OCT 2026 6:44PM by PIB Delhi The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has released a list of 543 brands of anti cancer medicines with their revised Maximum Retail Price (MRP). The revised MRPs will be effective from November 9, 2026. The revised price list reflects the information submitted by companies up to October 27, 2026 and it will be updated as and when manufacturers submit their revised prices of non-scheduled anti-cancer drugs.
Some brands of the anti cancer medicines with their pre-revised and revised prices:
Company Drug Name Strength Brand Pack Old MRP Revis Name & Name Size (โน) MRP Dosage Form RPG LIFE Anastrozole 1 MG ANARZOLE 10 695.76 73.0 SCIENCES LTD Tablet tablets Dr. Reddys Azacitidine 100 MG Azacytin 1 6,337.00 1,495 Laboratories Injection Limited Abbott Bevacizumab 100 BEVACIZAB 4 ml vial 21,767.70 5,930 Healthcare Pvt. mg/4 ml Ltd. Injection NATCO Dasatinib 20 MG Dasanat 60 2,812.50 1,085 PHARMA Tablet 20 tablets LIMITEDRPG LIFE Denosumab 60 MG Debrumab 1 ml PFS 22,031.25 5,941 SCIENCES LTD Injection 60 mg RPG LIFE Enzalutamide 40 MG Enuta 28 6,578.20 2,232 SCIENCES LTD Capsule capsules NEON Erlotinib 150 MG ERLIB 1 Plastic 4,637.45 2,008 LABORATORIES Tablet Bottle of LIMITED 30 tablets HETERO Fludarabine 50 MG FLUDANOX vial 14,235.00 2,432 HEALTHCARE Injection LTD RPG LIFE Fulvestrant 50 MG Fulbreca 5 ml vial 26,072.16 5,491 SCIENCES LTD Injection The complete list of 543 brands of Anti-Cancer medicines with revised MRPs is available here. (LINK). The NPPA portal is updated on a continual basis.
On October 17, 2026, NPPA had announced Trade Margin Rationalisation (TMR) of 137 non-scheduled anti-cancer drugs in public interest to address excessive trade margins, make cancer treatment more affordable and improve access to anti-cancer medicines.
Manufacturers were instructed to submit their revised list to NPPA.
The 137 non-scheduled anti-cancer drugs include immunotherapy medicines used in the treatment of over 20 types of cancer, Denosumab used by breast and prostate cancer patients, Pegfilgrastim used to prevent neutropenia in cancer patients, and Bevacizumab, which is approved for the treatment of colon, ovarian and cervical cancers.
***** PC/PM (Release ID: 2329698)Visitor Counter : 1665
Read this release in: Urdu , เคนเคจเฅเคฆเฅ , Tamil Share 350 words | 1 min read